The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy

Endocrinology

Volumn 146, Issue 8, 2005, Pages 3235-3243

  Morony, Sean ^a   Warmington, Kelly ^a   Adamu, Stephen ^a   Asuncion, Frank ^a   Geng, Zhaopo ^a   Grisanti, Mario ^a   Hong, Lin Tan ^a   Capparelli, Casey ^a   Starnes, Charlie ^a   Weimann, Bernadette ^a   Dunstan, Colin R ^a,b   Kostenuik, Paul J ^a  

^a AMGEN INC   (United States)

^b ANZAC RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN RECEPTOR; RECOMBINANT PROTEIN; ZOLEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CELL SURFACE; CONTROLLED STUDY; HYPERCALCEMIA; INOCULATION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BONE RESORPTION; CALCIUM; CARRIER PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; GLYCOPROTEINS; HUMANS; HYPERCALCEMIA; LIGANDS; MEMBRANE GLYCOPROTEINS; MICE; NF-KAPPA B; OSTEOPROTEGERIN; PARATHYROID HORMONE-RELATED PROTEIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 23044509872     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-1583     Document Type: Article

References (62)

1. Thiebaud D, Jaeger P, Burckhardt P 1990 Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone. J Bone Miner Res 5:221-226
2. Dodwell DJ, Abbas SK, Morton AR, Howell A 1991 Parathyroid hormonerelated protein (50-69) and response to pamidronate therapy for tumor-induced hypercalcemia. Eur J Cancer 27:1629-1633
3. Harinck H, Bijvoet O, Plantingh A, Body JJ, Elte J, Sleeboom HP, Wildiers J, Neijt JP 1987 Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med 82:1133-1142
4. Grill V, Rankin W, Martin TJ 1998 Parathyroid hormone-related protein (PTHrP) and hypercalcemia. Eur J Cancer 34:222-229
5. Walls J, Ratcliffe WA, Howell A, Bundred NJ 1994 Parathyroid hormone and parathyroid hormone-related protein in the investigation of hypercalcemia in two hospital populations. Clin Endocrinol (Oxf) 41:407-413
6. Rizzoli R, Caverzasio J, Chapuy MC, Martin TJ, Bonjour JP 1989 Role of bone and kidney in parathyroid hormone-related peptide-induced hypercalcemia in rats. J Bone Miner Res 4:759-765
7. Walls J, Ratcliffe WA, Howell A, Bundred NJ 1994 Response to intravenous bisphosphonate therapy in hypercalcemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 70:169-172
8. Body JJ, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson A, Rubens RD 1998 Current use of bisphosphonates in oncology. J Clin Oncol 16:3890-3899
9. Pecherstorfer M, Schilling T, Blind E, Zimmer-Roth I, Baumgartner G, Ziegler R, Raue F 1994 Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 78:1268-1270
10. Hene RJ, Visser WJ, Duursma SA, Raymakers JA, De Bos Kuil RJ, Mees E 1990 No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy. Bone 11:15-20
11. O'Rourke NP, McCloskey EV, Rosini S, Coleman RE, Kanis JA 1994 Treatment of malignant hypercalcemia with aminohexane bisphosphonate (neridronate). Br J Cancer 69:914-917
12. Pecherstorfer M, Herrmann Z, Body JJ, Manegold C, Degardin M, Clemens MR, Thurlimann B, Tubiana-Hulin M, Steinhauer EU, van Eijkeren M, Huss HJ, Thiebaud D 1996 Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 14:268-276
13. Thiebaud D, Jaeger P, Jacquet AF, Burckhardt P 1988 Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 6:762-768
14. Yates A, Murray R, Jerums GJ, Martin TJ 1987 A comparison of single and multiple intravenous infusions of 3-amino-1-hydroxypropylidene-1,1- bisphosphonate (APD) in the treatment of hypercalcemia of malignancy. Austr NZ J Med 17:387-391
15. Ralston SH, Alzaid AA, Gallacher SJ, Gardner MD, Cowan RA, Boyle IT 1988 Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcemia. Q J Med 69:825-834
16. Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Richman SP, Tauer K, Neidhart J, Mallette LE, Siegel R, VandPol CJ 1992 Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancerrelated hypercalcemia. J Clin Oncol 10:134-142
17. Ralston SH, Thiebaud D, Herrmann Z, Steinhauer EU, Thurlimann B, Walls J, Lichinitser MR, Rizzoli R, Hagberg H, Huss HJ, Tubiana-Hulin M, Body JJ 1997 Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia. Br J Cancer 75:295-300
18. Body JJ, Louviaux I, Dumon JC 2000 Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Support Care Cancer 8:398-404
19. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body JJ, Quebe-Fehling E, Seaman J 2001 Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558-567
20. Takahashi K, Shirahata A, Fukushima S, Kokubo S, Teramura K, Usuda S 1998 Effects of YM175, a new-generation bisphosphonate, on hypcercalcemia induced by tumor-derived bone resorbing factors in rats. Jpn J Pharmacol 76:155-163
21. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577-2586
22. Sato M, Grasser WA, Endo N, Akins R, Simmons HA, Thompson DD, Golub EE, Rodan GA 1991 Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105
23. Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche H 1999 Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768-1778
24. Miller SC, Jee W, Kimmel DB, Woodburry L 1977 Ethane-1-hydroxy-1,1- diphosphonate (EHDP) effects on incorporation and accumulation of osteoclast nuclei. Calcif Tissue Int 22:243-252
25. Marshall MJ, Wilson AS, Davie M 1990 Effects of (3-amino-1- hydroxypropylidene)-1,1-bisphosphonate on mouse osteoclasts. J Bone Miner Res 5:955-962
26. Marshall MJ, Holt I, Davie M 1993 Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate. Calcif Tissue Int 52:21-25
27. Marie PJ, Hott M, Garba MT 1985 Inhibition of bone matrix apposition by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (AHPrBP) in the mouse. Bone 6:193-200
28. Seedor JG, Quartuccio HA, Thompson DD 1991 The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Mineral Res 6:339-346
29. Simonet WS, Lacey DL, Dunstan C, Kelly M, Chang MS, Luthy R, Nhuyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliot R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309-319
30. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan C, Burgess T, Elliot R, Colombero A, Elliot G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176
31. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179
32. Burgess T, Qian YX, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538
33. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan C, Lacey DL, Mak TW, Boyle WJ, Penninger JM 1999 OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis. Nature 397:315-323
34. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435-448
35. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliot R, Scully S, Van G, Kaufman S, Juan SC, Sun Y, Tarpley J, Martin L, Christensen K, McCabe J, Kostenuik PJ, Hsu H, Fletcher F, Dunstan CR, Lacey DL, Boyle WJ 2000 RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis, and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 97:1566-1571
36. Capparelli C, Morony S, Warmington K, Adamm S, Lacey D, Dunston CR, Stouch B, Martin S, Kostenuik PJ 2003 Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacoknetic analysis in rats. J Bone Miner Res 18:852-858
37. Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan CR 2000 Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 60:783-787
38. Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR 2001 Therapeutic efficacy of a soluble receptor activator of nuclear factor aB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 61:2572-2578
39. Yamamoto M, Murakami T, Nishikawa M, Tsuda E, Mochizuki SI, Higashio K, Akatsu T, Motoyoshi K, Nagata N 1998 Hypocalcemic effect of osteoclastogenesis inhibitory factor/osteoprotegerin in the thyroparathyroidectomized rat. Endocrinology 139:4012-4015
40. Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki SI, Fujise N, Higashio K, Motoyoshi K, Yamamoto M, Nagata N 1998 Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 23:495-498
41. Kautiainen S, Luurila S, Ylitalo P, Ylitalo R 1998 Transformation of bisphosphonates into insoluble material in human blood in vitro. Methods Find Exp Clin Pharmacol 20:289-295
42. Morton AR, Cantrill JA, Craig AE, Howell A, Davies M, Anderson DC 1988 Single dose versus daily intravenous aminohydroxypropylidene bisphosphonate (APD) for the hypercalcemia of malignancy. Br Med J 296:811-814
43. Ralston SH, Gallacher SJ, Patel U, Dryburgh FJ, Fraser WD, Cowan RA, Boyle IT 1989 Comparison of three intravenous bisphosphonates in cancer-associated hypercalcemia. Lancet 2:1180-1182
44. Thiebaud D, Portmann L, Jaeger P, Jacquet AF, Burckhardt P 1986 Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy. Bone 7:247-253
45. Wuster C, Schoter KH, Thiebaud D, Manegold C, Krahl D, Clemens MR, Ghielmini M, Jaeger P, Scharla SH 1993 Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Miner 22:77-85
46. Gurney H, Kefford R, Stuart-Harris R 1989 Renal phosphate threshold and response to pamidronate in humoral hypercalcemia of malignancy. Lancet 29:241-243
47. Ralston SH, Gardner MD, Dryburgh FJ, Jenkins AS, Cowan RA, Boyle IT 1985 Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcemia. Lancet 26:907-910
48. Davis J, Heath DA 1989 Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcemia of malignancy. Br J Clin Pharmacol 28:269-274
49. Gallacher SJ, Fraser WD, Logue FC, Dryburgh FJ, Cowan RA, Boyle IT, Ralston SH 1992 Factors predicting the acute effect of pamidronate on serum calcium in hypercalcemia of malignancy. Calcif Tissue Int 51:419-423
50. Chang JT, Green L, Beitz J 2003 Renal failure with the use of zoledronic acid. N Engl J Med 349:1676-1679
51. Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W, Park J, Nasr SH, Hoh S, Siegel DS, D'Agati VD 2003 Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64:281-289
52. 3. J Bone Miner Res 14:1478-1485
53. Hock JM, Fonseca J, Gunness-Hey M, Kemp BE, Martin TJ 1989 Comparison of the anabolic effects of synthetic parathyroid hormone-related protein (PTHrP) 1-34 and PTH 1-34 on bone in rats. Endocrinology 125:2022-2027
54. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Mede 349:1207-1215
55. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
56. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen M 1998 The anabolic effect of human PTH-(1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate: is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system. Bone 16:603-610
57. Redlich K, Gortz B, Hayer S, Zwerina J, Doerr N, Kostenuik PJ, Bergmeister H, Kollias G, Steiner G, Smolen JS, Schett G 2004 Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis. Am J Pathol 164:543-555
58. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR 2001 OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142:4295-4305
59. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR 2001 The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360
60. Hoggarth CR, Bennett R, Daley-Yates PT 1991 The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse. Calcif Tissue Int 49:416-420
61. Cal JC, Daley-Yates PT 1990 Deposition and nephrotoxicity of 3-amino-1-hydroxypropylidene-1,1-bisphosponate (APD), in rats and mice. Toxicology 65:179-197
62. Pysklywec MW, Moran EL, Bogoch ER 2000 Changes in cross-sectional geometry of the distal femoral metaphysis associated with inflammatory arthritis are reduced by a bisphosphonate (Zoledronate). J Orthopaed Res 18:734-738